

Eric Solary

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6524965/eric-solary-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

362
papers

26,060
citations

82
h-index

150
g-index

391
ext. papers

29,341
ext. citations

7.2
avg. IF

6.37
L-index

#	Paper	IF	Citations
362	UBA1 gene mutation in giant cell arteritis.. <i>Clinical Rheumatology</i> , 2022 , 41, 1257	3.9	2
361	Macrophage migration inhibitory factor is overproduced through EGR1 in TET2 resting monocytes.. <i>Communications Biology</i> , 2022 , 5, 110	6.7	0
360	Reprogramming monocyte-derived macrophages through caspase inhibition.. <i>Oncolmunology</i> , 2022 , 11, 2015859	7.2	0
359	Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients. <i>EBioMedicine</i> , 2022 , 80, 104077	8.8	2
358	Asxl1 loss cooperates with oncogenic Nras in mice to reprogram immune microenvironment and drive leukemic transformation. <i>Blood</i> , 2021 ,	2.2	1
357	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. <i>Cell Death and Disease</i> , 2021 , 12, 258	9.8	37
356	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. <i>Blood Cancer Journal</i> , 2021 , 11, 54	7	1
355	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. <i>Nature Communications</i> , 2021 , 12, 2901	17.4	12
354	Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021 , 35, 2739-2751	10.7	3
353	Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML. <i>Blood</i> , 2021 , 137, 3390-3402	2.2	7
352	Chronic Myelomonocytic Leukemia Gold Jubilee. <i>Hemato</i> , 2021 , 2, 403-428	0.2	
351	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2021 , 28, 3297-3315	12.7	7
350	Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study. <i>Leukemia</i> , 2021 , 35, 893-896	10.7	1
349	Identifying key questions in the ecology and evolution of cancer. <i>Evolutionary Applications</i> , 2021 , 14, 877-892	4.8	17
348	Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting. <i>European Journal of Health Economics</i> , 2021 , 22, 855-864	3.6	2
347	Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN γ in myeloproliferative neoplasms. <i>Blood</i> , 2021 , 138, 2231-2243	2.2	8
346	No impact of cancer and plague-relevant polymorphisms on COVID-19. <i>Oncolmunology</i> , 2020 , 9, 1857142	2	2

345	Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. <i>Oncogene</i> , 2020 , 39, 5323-5337	9.2	7
344	The role of host environment in cancer evolution. <i>Evolutionary Applications</i> , 2020 , 13, 1756-1770	4.8	7
343	Donor Lymphocyte Infusions After Allogeneic Transplantation: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 209-211	2	4
342	Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic. <i>American Journal of Hematology</i> , 2020 , 95, E203-E208	7.1	7
341	Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study. <i>Blood</i> , 2020 , 136, 15-16	2.2	2
340	Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dakota Trial. <i>Blood</i> , 2020 , 136, 53-54	2.2	19
339	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 242-255	12.9	55
338	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. <i>Leukemia</i> , 2020 , 34, 1407-1421	10.7	40
337	Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review. <i>Autoimmunity Reviews</i> , 2020 , 19, 102446	13.6	11
336	Incorporating flow cytometry and next-generation sequencing in the diagnosis of CMML. Are we ready for prime?. <i>Best Practice and Research in Clinical Haematology</i> , 2020 , 33, 101134	4.2	2
335	Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 879-884	5.3	7
334	Towards a cancer mission in Horizon Europe: recommendations. <i>Molecular Oncology</i> , 2020 , 14, 1589-1615	5.9	15
333	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. <i>Cell</i> , 2020 , 182, 1401-1418.e18	56.2	359
332	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. <i>Npj Precision Oncology</i> , 2020 , 4, 27	9.8	3
331	Tracking chronic myelomonocytic leukaemia diversity at the single cell level. <i>EBioMedicine</i> , 2020 , 59, 102935	8.8	
330	Immune responses during COVID-19 infection. <i>OncImmunity</i> , 2020 , 9, 1807836	7.2	49
329	Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2020 , 105, 112-123	6.6	8
328	HIV-1 Envelope Overcomes NLRP3-Mediated Inhibition of F-Actin Polymerization for Viral Entry. <i>Cell Reports</i> , 2019 , 28, 3381-3394.e7	10.6	10

327	Towards a classification of 'stem' cells. <i>ELife</i> , 2019 , 8,	8.9	12
326	Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study. <i>Cancer Medicine</i> , 2019 , 8, 3296-3304	4.8	9
325	Dynamic gene regulation by nuclear colony-stimulating factor 1 receptor in human monocytes and macrophages. <i>Nature Communications</i> , 2019 , 10, 1935	17.4	12
324	Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2019 , 33, 2466-2480	10.7	37
323	Serpin B1 defect and increased apoptosis of neutrophils in Cohen syndrome neutropenia. <i>Journal of Molecular Medicine</i> , 2019 , 97, 633-645	5.5	11
322	Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum. <i>Blood</i> , 2019 , 133, 2718-2724	2.2	19
321	Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with associated inflammatory state. <i>Haematologica</i> , 2019 ,	6.6	10
320	Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. <i>Leukemia</i> , 2019 , 33, 205-216	10.7	30
319	MUB Binds to Lactoferrin and Stands as a Specific Neutrophil Marker. <i>Cell Chemical Biology</i> , 2018 , 25, 483-493.e9	8.2	7
318	Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2503-2505	1.9	2
317	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. <i>European Journal of Cancer</i> , 2018 , 92, 1-10	7.5	11
316	Myelodysplastic Syndromes: Mechanisms, Diagnosis, and Treatment 2018 , 563-563		
315	Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents. <i>EBioMedicine</i> , 2018 , 31, 174-181	8.8	49
314	Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. <i>Cancer Journal (Sudbury, Mass)</i> , 2018 , 24, 153-162	2.2	11
313	Chronic Myelomonocytic Leukemia (CMML). <i>Hematologic Malignancies</i> , 2018 , 65-79	0	
312	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018 , 9, 9741-9750	3.3	7
311	High sensitivity of the Hematoflow ³ resolution for chronic myelomonocytic leukemia screening. <i>Cytometry Part B - Clinical Cytometry</i> , 2018 , 94, 658-661	3.4	8
310	Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1742-1745	1.9	6

309	Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis. <i>Blood Cancer Journal</i> , 2018 , 8, 114	7	11
308	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. <i>HemaSphere</i> , 2018 , 2, e150	0.3	48
307	A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset. <i>Nature Communications</i> , 2018 , 9, 5455	17.4	22
306	Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?. <i>European Journal of Cancer</i> , 2018 , 103, 108-119	7.5	12
305	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. <i>Blood Cancer Journal</i> , 2018 , 8, 82	7	14
304	Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease. <i>Leukemia Research</i> , 2017 , 55, 58-64	2.7	2
303	Non-apoptotic functions of caspases in myeloid cell differentiation. <i>Cell Death and Differentiation</i> , 2017 , 24, 1337-1347	12.7	26
302	CMML: Clinical and molecular aspects. <i>International Journal of Hematology</i> , 2017 , 105, 711-719	2.3	26
301	ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. <i>Nature Communications</i> , 2017 , 8, 15429	17.4	38
300	Turning the tide in myelodysplastic/myeloproliferative neoplasms. <i>Nature Reviews Cancer</i> , 2017 , 17, 425-440	3.45	91
299	Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2875-2879	1.9	2
298	DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues. <i>Cell Death and Disease</i> , 2017 , 8, e2816	9.8	14
297	How I treat chronic myelomonocytic leukemia. <i>Blood</i> , 2017 , 130, 126-136	2.2	62
296	NOX2-dependent ATM kinase activation dictates pro-inflammatory macrophage phenotype and improves effectiveness to radiation therapy. <i>Cell Death and Differentiation</i> , 2017 , 24, 1632-1644	12.7	26
295	Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. <i>Blood</i> , 2017 , 130, 832-835	2.2	39
294	A constitutive BCL2 down-regulation aggravates the phenotype of PKD1-mutant-induced polycystic kidney disease. <i>Human Molecular Genetics</i> , 2017 , 26, 4680-4688	5.6	6
293	Resveratrol stimulates the metabolic reprogramming of human CD4 T cells to enhance effector function. <i>Science Signaling</i> , 2017 , 10,	8.8	16
292	Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. <i>PLoS ONE</i> , 2017 , 12, e0188174	3.7	65

291	The severe phenotype of Diamond-Blackfan anemia is modulated by heat shock protein 70. <i>Blood Advances</i> , 2017 , 1, 1959-1976	7.8	19
290	Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. <i>Blood Cancer Journal</i> , 2017 , 7, e584	7	49
289	Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents. <i>Blood Cancer Journal</i> , 2017 , 7, e562	7	12
288	Modulation of the inwardly rectifying potassium channel Kir4.1 by the pro-invasive miR-5096 in glioblastoma cells. <i>Oncotarget</i> , 2017 , 8, 37681-37693	3.3	28
287	CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. <i>Oncotarget</i> , 2017 , 8, 54082-54095	3.3	22
286	Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines. <i>Blood Advances</i> , 2017 , 1, 972-979	7.8	19
285	The Microvascular Gap Junction Channel: A Route to Deliver MicroRNAs for Neurological Disease Treatment. <i>Frontiers in Molecular Neuroscience</i> , 2017 , 10, 246	6.1	6
284	Serum Gp96 is a chaperone of complement-C3 during graft-versus-host disease. <i>JCI Insight</i> , 2017 , 2, e90531	9.9	10
283	The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development. <i>Oncogene</i> , 2016 , 35, 2842-51	9.2	18
282	CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress. <i>Scientific Reports</i> , 2016 , 6, 37827	4.9	48
281	Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. <i>Blood</i> , 2016 , 127, 749-60	2.2	34
280	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. <i>Nature Communications</i> , 2016 , 7, 10767	17.4	140
279	The guardians of inherited oncogenic vulnerabilities. <i>Evolution; International Journal of Organic Evolution</i> , 2016 , 70, 1-6	3.8	10
278	Comprehensive Inflammatory Cytokine Profiling Identifies IL-8/CXCL8 As Elevated, Associated with Proliferative Features, and Independently Prognostic in Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2016 , 128, 109-109	2.2	1
277	A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. <i>Blood</i> , 2016 , 128, 4320-4320	2.2	4
276	Gap junction-mediated transfer of miR-145-5p from microvascular endothelial cells to colon cancer cells inhibits angiogenesis. <i>Oncotarget</i> , 2016 , 7, 28160-8	3.3	55
275	Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT. <i>PLoS ONE</i> , 2016 , 11, e0160165	3.7	7
274	Transfer of functional microRNAs between glioblastoma and microvascular endothelial cells through gap junctions. <i>Oncotarget</i> , 2016 , 7, 73925-73934	3.3	37

273	Do cell-autonomous and non-cell-autonomous effects drive the structure of tumor ecosystems?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016 , 1865, 147-54	11.2	6
272	Unplugging JAK/STAT in Chronic Myelomonocytic Leukemia. <i>Clinical Cancer Research</i> , 2016 , 22, 3707-9	12.9	7
271	Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. <i>Blood Cancer Journal</i> , 2015 , 5, e270	7	21
270	Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. <i>Blood</i> , 2015 , 125, 3618-26	2.2	146
269	An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. <i>Blood Cancer Journal</i> , 2015 , 5, e333	7	89
268	An International MDS/MPN Working Group perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. <i>Haematologica</i> , 2015 , 100, 1117-30	6.6	79
267	Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. <i>Nature Genetics</i> , 2015 , 47, 1131-40	36.3	83
266	Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. <i>Leukemia</i> , 2015 , 29, 249-52	10.7	68
265	Concise Review: Induced Pluripotent Stem Cells as New Model Systems in Oncology. <i>Stem Cells</i> , 2015 , 33, 2887-92	5.8	8
264	Cancer: an emergent property of disturbed resource-rich environments? Ecology meets personalized medicine. <i>Evolutionary Applications</i> , 2015 , 8, 527-40	4.8	18
263	Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. <i>Blood</i> , 2015 , 125, 930-40	2.2	66
262	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. <i>Blood</i> , 2015 , 125, 1857-65	2.2	118
261	Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. <i>Blood</i> , 2015 , 126, 1106-17	2.2	310
260	Can Peto paradox be used as the null hypothesis to identify the role of evolution in natural resistance to cancer? A critical review. <i>BMC Cancer</i> , 2015 , 15, 792	4.8	11
259	The impact of tumor nitric oxide production on VEGFA expression and tumor growth in a zebrafish rat glioma xenograft model. <i>PLoS ONE</i> , 2015 , 10, e0120435	3.7	16
258	Death Receptor-Induced Apoptosis Signalling Regulation by Ezrin Is Cell Type Dependent and Occurs in a DISC-Independent Manner in Colon Cancer Cells. <i>PLoS ONE</i> , 2015 , 10, e0126526	3.7	7
257	The PRKAA1/AMPK pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMML. <i>Autophagy</i> , 2015 , 11, 1114-29	10.2	64
256	Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. <i>Journal of Clinical Investigation</i> , 2015 , 125, 1857-72	15.9	129

255	A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM. <i>Blood</i> , 2015 , 126, 2872-2872	2.2	1
254	H89 enhances the sensitivity of cancer cells to glyceryl trinitrate through a purinergic receptor-dependent pathway. <i>Oncotarget</i> , 2015 , 6, 6877-86	3.3	10
253	Oncogenic extracellular HSP70 disrupts the gap-junctional coupling between capillary cells. <i>Oncotarget</i> , 2015 , 6, 10267-83	3.3	13
252	Primary tumor- and metastasis-derived colon cancer cells differently modulate connexin expression and function in human capillary endothelial cells. <i>Oncotarget</i> , 2015 , 6, 28800-15	3.3	26
251	HSP70, the Key to Account for Erythroid Tropism of Diamond-Blackfan Anemia?. <i>Blood</i> , 2015 , 126, 671-671		
250	JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. <i>Leukemia</i> , 2014 , 28, 338-48	10.7	105
249	Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFN α treatment. <i>Leukemia</i> , 2014 , 28, 460-3	10.7	10
248	The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. <i>Leukemia</i> , 2014 , 28, 485-96	10.7	179
247	clAP1 regulates TNF-mediated cdc42 activation and filopodia formation. <i>Oncogene</i> , 2014 , 33, 5534-45	9.2	15
246	Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. <i>Blood</i> , 2014 , 123, 1372-83	2.2	59
245	Acquired initiating mutations in early hematopoietic cells of CLL patients. <i>Cancer Discovery</i> , 2014 , 4, 1088-1091	10.7	172
244	Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. <i>Journal of Clinical Oncology</i> , 2014 , 32, 297-305	2.2	94
243	Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice. <i>Current Hematologic Malignancy Reports</i> , 2014 , 9, 301-10	4.4	2
242	Dual regulation of SPI1/PU.1 transcription factor by heat shock factor 1 (HSF1) during macrophage differentiation of monocytes. <i>Leukemia</i> , 2014 , 28, 1676-86	10.7	25
241	Cohen syndrome is associated with major glycosylation defects. <i>Human Molecular Genetics</i> , 2014 , 23, 2391-9	5.6	55
240	TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells. <i>Stem Cells</i> , 2014 , 32, 2084-97	5.8	32
239	JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. <i>Blood</i> , 2014 , 124, 2104-15	2.2	34
238	Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication. <i>PLoS ONE</i> , 2014 , 9, e97519	3.7	10

237	ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. <i>Leukemia</i> , 2014 , 28, 2206-12	10.7	186
236	Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. <i>American Journal of Hematology</i> , 2014 , 89, 1111-5	7.1	104
235	The role of reactive oxygen species and subsequent DNA-damage response in the emergence of resistance towards resveratrol in colon cancer models. <i>Cell Death and Disease</i> , 2014 , 5, e1533	9.8	45
234	A role for peroxisome proliferator-activated receptor gamma in resveratrol-induced colon cancer cell apoptosis. <i>Molecular Nutrition and Food Research</i> , 2014 , 58, 1785-94	5.9	21
233	Circulating immature granulocytes with T-cell killing functions predict sepsis deterioration*. <i>Critical Care Medicine</i> , 2014 , 42, 2007-18	1.4	131
232	Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2014 , 89, 604-9	7.1	32
231	Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. <i>Journal of Clinical Investigation</i> , 2014 , 124, 580-91	15.9	119
230	Targeting apoptosis proteins in hematological malignancies. <i>Cancer Letters</i> , 2013 , 332, 325-34	9.9	19
229	An evolutionary perspective on chronic myelomonocytic leukemia. <i>Leukemia</i> , 2013 , 27, 1441-50	10.7	67
228	Extracellular HSP27 mediates angiogenesis through Toll-like receptor 3. <i>FASEB Journal</i> , 2013 , 27, 4169-83.9		80
227	Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?. <i>Best Practice and Research in Clinical Haematology</i> , 2013 , 26, 387-400	4.2	11
226	Clonal architecture of chronic myelomonocytic leukemias. <i>Blood</i> , 2013 , 121, 2186-98	2.2	189
225	Prognostic score including gene mutations in chronic myelomonocytic leukemia. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2428-36	2.2	373
224	A role for miR-142-3p in colony-stimulating factor 1-induced monocyte differentiation into macrophages. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2013 , 1833, 1936-46	4.9	37
223	Applying ecological and evolutionary theory to cancer: a long and winding road. <i>Evolutionary Applications</i> , 2013 , 6, 1-10	4.8	57
222	SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. <i>Leukemia</i> , 2013 , 27, 1401-3	10.7	88
221	Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. <i>Immunity</i> , 2013 , 38, 729-41	32.3	439
220	ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2013 , 368, 1101-10	59.2	284

219	A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. <i>Leukemia</i> , 2013 , 27, 2187-95	10.7	116
218	Developmental changes in human megakaryopoiesis. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 1730-41	15.4	52
217	Epigenetic control of NF- κ B-dependent FAS gene transcription during progression of myelodysplastic syndromes. <i>Molecular Cancer Research</i> , 2013 , 11, 724-35	6.6	13
216	TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. <i>EMBO Journal</i> , 2013 , 32, 645-55	13	359
215	Tubulin-targeting agent combination therapies: dosing schedule could matter. <i>British Journal of Pharmacology</i> , 2013 , 168, 1555-7	8.6	3
214	Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2013 , 27, 1946-9	10.7	32
213	Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. <i>Cell Death and Disease</i> , 2013 , 4, e738	9.8	27
212	BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. <i>Blood</i> , 2013 , 122, 3169-77	2.2	147
211	JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN γ . <i>Blood</i> , 2013 , 122, 1464-77	2.2	95
210	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. <i>Haematologica</i> , 2013 , 98, 1748-52	6.6	40
209	Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. <i>PLoS ONE</i> , 2013 , 8, e74257	3.7	23
208	Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. <i>Blood</i> , 2012 , 119, 1532-42	2.2	47
207	Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic functions. <i>Blood</i> , 2012 , 119, 4527-31	2.2	102
206	When monocyte life hangs by a thread. <i>Blood</i> , 2012 , 119, 2699-700	2.2	3
205	MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations. <i>Blood</i> , 2012 , 120, 2719-22	2.2	61
204	JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. <i>Oncogene</i> , 2012 , 31, 1323-33	9.2	76
203	Proper macrophagic differentiation requires both autophagy and caspase activation. <i>Autophagy</i> , 2012 , 8, 1141-3	10.2	24
202	Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations. <i>Cellular and Molecular Life Sciences</i> , 2012 , 69, 2853-61	10.3	3

201	Recent advances in chronic myelomonocytic leukemia. <i>Hematologie</i> , 2012 , 18, 24-36	0	
200	Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML. <i>Leukemia</i> , 2012 , 26, 2297-9	10.7	24
199	CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. <i>Cell Death and Disease</i> , 2012 , 3, e396	9.8	47
198	Current insights in the cellular and molecular biology of chronic myelomonocytic leukemia. <i>International Journal of Hematologic Oncology</i> , 2012 , 1, 147-158	1	1
197	Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia. <i>Oncotarget</i> , 2012 , 3, 1284-93	3.3	17
196	Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. <i>Blood Cancer Journal</i> , 2011 , 1, e7	7	11
195	TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT. <i>PLoS ONE</i> , 2011 , 6, e19679	3.7	50
194	A short caspase-3 isoform inhibits chemotherapy-induced apoptosis by blocking apoptosome assembly. <i>PLoS ONE</i> , 2011 , 6, e29058	3.7	25
193	Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy. <i>Haematologica</i> , 2011 , 96, 612-6	6.6	90
192	Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions. <i>Blood</i> , 2011 , 117, 3065-75	2.2	41
191	Fine-tuning nucleophosmin in macrophage differentiation and activation. <i>Blood</i> , 2011 , 118, 4694-704	2.2	25
190	Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. <i>Blood</i> , 2011 , 118, 3824-31	2.2	166
189	Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. <i>Cell Death and Differentiation</i> , 2011 , 18, 700-11	12.7	69
188	TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. <i>Cancer Cell</i> , 2011 , 20, 25-38	24.3	653
187	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis. <i>Cancer Cell</i> , 2011 , 20, 276	24.3	2
186	Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. <i>Current Medicinal Chemistry</i> , 2011 , 18, 1100-21	4.3	126
185	Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription. <i>Journal of Biological Chemistry</i> , 2011 , 286, 26406-17	5.4	29
184	Transactivation of the epidermal growth factor receptor by heat shock protein 90 via Toll-like receptor 4 contributes to the migration of glioblastoma cells. <i>Journal of Biological Chemistry</i> , 2011 , 286, 3418-28	5.4	73

183	Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. <i>Blood</i> , 2011 , 118, 2551-5	2.2	139
182	Endocytosis of resveratrol via lipid rafts and activation of downstream signaling pathways in cancer cells. <i>Cancer Prevention Research</i> , 2011 , 4, 1095-106	3.2	76
181	Transcription intermediary factor 1 α is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. <i>Journal of Clinical Investigation</i> , 2011 , 121, 2361-70	15.9	80
180	The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism. <i>Oncogene</i> , 2010 , 29, 2577-84	9.2	38
179	Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells. <i>Oncogene</i> , 2010 , 29, 5019-31	9.2	37
178	Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. <i>Leukemia</i> , 2010 , 24, 1094-6	10.7	201
177	Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2010 , 120, 457-71	15.9	651
176	Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. <i>Journal of Immunology</i> , 2010 , 184, 1876-84	5.3	43
175	Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia. <i>Blood</i> , 2010 , 115, 78-88	2.2	39
174	Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. <i>Blood</i> , 2010 , 115, 1690-6	2.2	186
173	HSP27 controls GATA-1 protein level during erythroid cell differentiation. <i>Blood</i> , 2010 , 116, 85-96	2.2	58
172	Comparative analysis of nonaspanin protein sequences and expression studies in zebrafish. <i>Immunogenetics</i> , 2010 , 62, 681-99	3.2	8
171	Myeloid-Derived Suppressive Cells Belonging to the Leukemic Clone Account for Immunosuppression In CMML. <i>Blood</i> , 2010 , 116, 3997-3997	2.2	3
170	Various functions of caspases in hematopoiesis. <i>Frontiers in Bioscience - Landmark</i> , 2009 , 14, 2358-71	2.8	6
169	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2009 , 94, 1676-81	6.6	198
168	Liver X receptor-mediated induction of cholesteryl ester transfer protein expression is selectively impaired in inflammatory macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009 , 29, 1923-9	9.4	20
167	Induction of transglutaminase 2 by a liver X receptor/retinoic acid receptor alpha pathway increases the clearance of apoptotic cells by human macrophages. <i>Circulation Research</i> , 2009 , 105, 393-401	15.7	75
166	Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer cells. <i>International Journal of Cancer</i> , 2009 , 124, 2780-8	7.5	108

165	Human defensins as cancer biomarkers and antitumour molecules. <i>Journal of Proteomics</i> , 2009 , 72, 918-279	3.7	103
164	Comparative analysis of zebrafish nos2a and nos2b genes. <i>Gene</i> , 2009 , 445, 58-65	3.8	55
163	clAP1-dependent TRAF2 degradation regulates the differentiation of monocytes into macrophages and their response to CD40 ligand. <i>Blood</i> , 2009 , 113, 175-85	2.2	29
162	FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. <i>Blood</i> , 2009 , 113, 3027-30	2.2	110
161	Colony-stimulating factor-1-induced oscillations in phosphatidylinositol-3 kinase/AKT are required for caspase activation in monocytes undergoing differentiation into macrophages. <i>Blood</i> , 2009 , 114, 3633-41	2.2	44
160	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). <i>Blood</i> , 2009 , 114, 3285-91	2.2	231
159	Spontaneous and Fas-induced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum. <i>Leukemia</i> , 2008 , 22, 1864-73	10.7	20
158	Interaction of heat-shock protein 90 beta isoform (HSP90 beta) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation. <i>Cell Death and Differentiation</i> , 2008 , 15, 859-66	12.7	40
157	Polyethylenimine-mediated in vivo gene transfer of a transmembrane superantigen fusion construct inhibits B16 murine melanoma growth. <i>Cancer Gene Therapy</i> , 2008 , 15, 742-9	5.4	11
156	MOZ/TIF2-induced acute myeloid leukaemia in transgenic fish. <i>British Journal of Haematology</i> , 2008 , 143, 378-82	4.5	58
155	A role for the transcription intermediary factor 2 in zebrafish myelopoiesis. <i>Experimental Hematology</i> , 2008 , 36, 559-67	3.1	4
154	PKC zeta controls DNA topoisomerase-dependent human caspase-2 pre-mRNA splicing. <i>FEBS Letters</i> , 2008 , 582, 372-8	3.8	10
153	Heat shock proteins: essential proteins for apoptosis regulation. <i>Journal of Cellular and Molecular Medicine</i> , 2008 , 12, 743-61	5.6	334
152	A role for caspases in the differentiation of erythroid cells and macrophages. <i>Biochimie</i> , 2008 , 90, 416-22	4.6	25
151	CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. <i>Journal of Clinical Investigation</i> , 2008 , 118, 3751-61	15.9	52
150	Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. <i>Cell Biology International</i> , 2008 , 32, 1031-43	4.5	165
149	Trefoil factor TFF1-induced protection of conjunctival cells from apoptosis at premitochondrial and postmitochondrial levels 2008 , 49, 3790-8		12
148	A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 2337-45	6.1	99

147	Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. <i>Nature</i> , 2007 , 445, 102-5	50.4	199
146	Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. <i>Clinical and Experimental Immunology</i> , 2007 , 150, 523-30	6.2	96
145	Imaging of nitric oxide in a living vertebrate using a diamino-fluorescein probe. <i>Free Radical Biology and Medicine</i> , 2007 , 43, 619-27	7.8	66
144	Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 641-8	7.4	944
143	Dendritic cells trigger tumor cell death by a nitric oxide-dependent mechanism. <i>Journal of Immunology</i> , 2007 , 179, 812-8	5.3	31
142	Caspase-8 prevents sustained activation of NF-kappaB in monocytes undergoing macrophagic differentiation. <i>Blood</i> , 2007 , 109, 1442-50	2.2	104
141	TRAIL in cancer therapy: present and future challenges. <i>Expert Opinion on Therapeutic Targets</i> , 2007 , 11, 1299-314	6.4	124
140	Topoisomerase I Poisons and Apoptotic Topoisomerase I-DNA Complexes 2007 , 383-406		
139	Fas-Dependent Apoptosis in Early MDS Erythroid Precursors Involves Endoplasmic Reticulum.. <i>Blood</i> , 2007 , 110, 3346-3346	2.2	
138	Identification of proteins cleaved downstream of caspase activation in monocytes undergoing macrophage differentiation. <i>Journal of Biological Chemistry</i> , 2006 , 281, 17779-88	5.4	45
137	Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. <i>Molecular and Cellular Biology</i> , 2006 , 26, 7046-55	4.8	241
136	Differential mechanisms of conjunctival cell death induction by ultraviolet irradiation and benzalkonium chloride. <i>Investigative Ophthalmology and Visual Science</i> , 2006 , 47, 4221-30		35
135	Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. <i>Cancer Research</i> , 2006 , 66, 4191-7	10.1	126
134	Nitric oxide-induced down-regulation of beta-catenin in colon cancer cells by a proteasome-independent specific pathway. <i>Gastroenterology</i> , 2006 , 131, 1142-52	13.3	23
133	HSP27 favors ubiquitination and proteasomal degradation of p27Kip1 and helps S-phase re-entry in stressed cells. <i>FASEB Journal</i> , 2006 , 20, 1179-81	0.9	83
132	Mitochondria in hematopoiesis and hematological diseases. <i>Oncogene</i> , 2006 , 25, 4757-67	9.2	68
131	Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells. <i>Oncogene</i> , 2006 , 25, 7635-45	5.2	24
130	Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006 , 11, 1513-24	5.4	34

129	Both the Endoplasmic Reticulum and the Mitochondria Are Involved in Apoptosis of Erythroid Precursors in Low Grade Myelodysplastic Syndromes.. <i>Blood</i> , 2006 , 108, 2638-2638	2.2	
128	Trefoil factor family mRNA and protein expression in pterygium 2005 , 27, 997		3
127	Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. <i>Journal of Experimental Medicine</i> , 2005 , 202, 919-29	16.6	592
126	Identification of a functional DNA binding site for the SREBP-1c transcription factor in the first intron of the human caspase-2 gene. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2005 , 1738, 1-5	5	12
125	Small heat shock proteins HSP27 and alphaB-crystallin: cytoprotective and oncogenic functions. <i>Antioxidants and Redox Signaling</i> , 2005 , 7, 404-13	8.4	130
124	Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. <i>Blood</i> , 2005 , 106, 1063-6	2.2	214
123	Nonsense-mediated mRNA decay among human caspases: the caspase-2S putative protein is encoded by an extremely short-lived mRNA. <i>Cell Death and Differentiation</i> , 2005 , 12, 687-9	12.7	24
122	Vital functions for lethal caspases. <i>Oncogene</i> , 2005 , 24, 5137-48	9.2	177
121	Cellular localisation of survivin: impact on the prognosis in colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005 , 131, 504-10	4.9	42
120	A role for PKCzeta in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmannin. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 1457-64	6.1	8
119	Caspase-2, a novel lipid sensor under the control of sterol regulatory element binding protein 2. <i>Molecular and Cellular Biology</i> , 2005 , 25, 9621-31	4.8	41
118	Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. <i>Journal of Experimental Medicine</i> , 2005 , 201, 465-71	16.6	162
117	Increased immunogenicity of colon cancer cells by selective depletion of cytochrome C. <i>Cancer Research</i> , 2004 , 64, 2705-11	10.1	17
116	Translocation of the inhibitor of apoptosis protein c-IAP1 from the nucleus to the Golgi in hematopoietic cells undergoing differentiation: a nuclear export signal-mediated event. <i>Blood</i> , 2004 , 104, 2035-43	2.2	48
115	Apoptotic topoisomerase I-DNA complexes induced by staurosporine-mediated oxygen radicals. <i>Journal of Biological Chemistry</i> , 2004 , 279, 50499-504	5.4	57
114	Casein kinase II-mediated phosphorylation of NF-kappaB p65 subunit enhances inducible nitric-oxide synthase gene transcription in vivo. <i>Journal of Biological Chemistry</i> , 2004 , 279, 23953-60	5.4	40
113	Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. <i>Cancer Research</i> , 2004 , 64, 3593-8	10.1	268
112	Analyzing markers of apoptosis in vitro. <i>Methods in Molecular Biology</i> , 2004 , 281, 313-31	1.4	14

111	Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. <i>Oncogene</i> , 2004 , 23, 8979-86	9.2	161
110	CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. <i>European Journal of Immunology</i> , 2004 , 34, 336-44	6.1	758
109	Tumor cell resistance to DNA-damaging agents: from apoptosis to neiosis. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2004 , 4, 461-3		5
108	Topoisomerase I and II Inhibitors Control Caspase-2 Pre-Messenger RNA Splicing in Human Cells. <i>Molecular Cancer Research</i> , 2004 , 2, 53-61	6.6	49
107	Mitochondria as a target for inducing death of malignant hematopoietic cells. <i>Leukemia and Lymphoma</i> , 2003 , 44, 563-74	1.9	40
106	Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. <i>Journal of Biological Chemistry</i> , 2003 , 278, 41482-90	5.4	203
105	HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation. <i>Molecular and Cellular Biology</i> , 2003 , 23, 5790-802	4.8	268
104	LF 15-0195 immunosuppressive agent enhances activation-induced T-cell death by facilitating caspase-8 and caspase-10 activation at the DISC level. <i>Blood</i> , 2003 , 101, 194-201	2.2	13
103	Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. <i>Blood</i> , 2003 , 102, 1202-10	2.2	75
102	Subcellular expression of c-IAP1 and c-IAP2 in colorectal cancers: relationships with clinicopathological features and prognosis. <i>Pathology Research and Practice</i> , 2003 , 199, 723-31	3.4	21
101	Freshly isolated bone marrow cells induce death of various carcinoma cell lines. <i>International Journal of Cancer</i> , 2003 , 107, 747-56	7.5	16
100	A role of HSPs in apoptosis through "protein triage"?. <i>Cell Death and Differentiation</i> , 2003 , 10, 619-20	12.7	41
99	Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. <i>Oncogene</i> , 2003 , 22, 1807-16	9.2	112
98	The human caspase-2 gene: alternative promoters, pre-mRNA splicing and AUG usage direct isoform-specific expression. <i>Oncogene</i> , 2003 , 22, 935-46	9.2	38
97	Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. <i>Biochemical and Biophysical Research Communications</i> , 2003 , 304, 505-12	3.4	287
96	Bcl-2 proteins: targets and tools for chemosensitisation of tumor cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2003 , 3, 307-18		27
95	Implications physiopathologiques des altérations des gènes impliqués dans la régulation de la mort cellulaire. <i>Medecine/Sciences</i> , 2002 , 18, 861-873		
94	Intracellular redistribution of procaspases during TPA-induced differentiation of U937 human leukemic cells. <i>Leukemia</i> , 2002 , 16, 1569-70	10.7	8

93	An atypical caspase-independent death pathway for an immunogenic cancer cell line. <i>Oncogene</i> , 2002 , 21, 6091-100	9.2	13
92	Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571. <i>Leukemia</i> , 2002 , 16, 1154-9	10.7	8
91	CELL DEATH PATHWAYS AS TARGETS FOR ANTICANCER DRUGS 2002 , 55-76		2
90	Specific involvement of caspases in the differentiation of monocytes into macrophages. <i>Blood</i> , 2002 , 100, 4446-53	2.2	261
89	Influence of the nitric oxide donor glyceryl trinitrate on apoptotic pathways in human colon cancer cells. <i>Gastroenterology</i> , 2002 , 123, 235-46	13.3	64
88	Stage-dependent activation of cell cycle and apoptosis mechanisms in the right ventricle by pressure overload. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2002 , 1586, 233-42	6.9	22
87	Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells. <i>Cancer Letters</i> , 2002 , 185, 181-9	9.9	26
86	Atypical protein kinase C zeta as a target for chemosensitization of tumor cells. <i>Cancer Research</i> , 2002 , 62, 1815-21	10.1	26
85	Involvement of caspase-2 long isoform in Fas-mediated cell death of human leukemic cells. <i>Blood</i> , 2001 , 97, 1835-44	2.2	54
84	Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. <i>Blood</i> , 2001 , 97, 3931-40	2.2	78
83	Early increase in DcR2 expression and late activation of caspases in the platelet storage lesion. <i>Leukemia</i> , 2001 , 15, 1572-81	10.7	50
82	Modulation of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization. <i>Oncogene</i> , 2001 , 20, 260-9	9.2	32
81	Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. <i>Oncogene</i> , 2001 , 20, 1852-9	9.2	74
80	Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells. <i>Oncogene</i> , 2001 , 20, 7478-85	9.2	69
79	Caspase activation is required for terminal erythroid differentiation. <i>Journal of Experimental Medicine</i> , 2001 , 193, 247-54	16.6	338
78	Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. <i>Journal of Immunology</i> , 2001 , 167, 5077-83	5.3	57
77	Caffeine sensitizes human H358 cell line to p53-mediated apoptosis by inducing mitochondrial translocation and conformational change of BAX protein. <i>Journal of Biological Chemistry</i> , 2001 , 276, 38980-7	5.4	34
76	BCR-ABL fails to inhibit apoptosis in U937 myelomonocytic cells expressing a carboxyl-terminal truncated STAT5. <i>Leukemia and Lymphoma</i> , 2001 , 42, 445-55	1.9	5

75	Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. <i>International Journal of Cancer</i> , 2000 , 86, 827-34	7.5	18
74	Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. <i>Leukemia</i> , 2000 , 14, 1833-49	10.7	123
73	Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes. <i>Leukemia</i> , 2000 , 14, 2085-94	10.7	26
72	Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. <i>Oncogene</i> , 2000 , 19, 4855-63	9.2	119
71	Hsp27 negatively regulates cell death by interacting with cytochrome c. <i>Nature Cell Biology</i> , 2000 , 2, 645-52	23.4	798
70	Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. <i>British Journal of Haematology</i> , 2000 , 111, 801-806	4.5	8
69	Cutting edge: the tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. <i>Journal of Immunology</i> , 2000 , 164, 5023-7	5.3	65
68	Effects of cyclosporin at various concentrations on dexamethasone intracellular uptake in multidrug resistant cells. <i>Annals of the Rheumatic Diseases</i> , 2000 , 59, 146-8	2.4	10
67	Role of tumor cell apoptosis in tumor antigen migration to the draining lymph nodes. <i>Journal of Immunology</i> , 2000 , 164, 1995-2000	5.3	38
66	Dobutamine stress echocardiography identifies anthracycline cardiotoxicity. <i>European Journal of Echocardiography</i> , 2000 , 1, 180-3		23
65	The viral nucleocapsid protein of transmissible gastroenteritis coronavirus (TGEV) is cleaved by caspase-6 and -7 during TGEV-induced apoptosis. <i>Journal of Virology</i> , 2000 , 74, 3975-83	6.6	75
64	Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. <i>British Journal of Haematology</i> , 2000 , 111, 801-6	4.5	104
63	HSP27 inhibits cytochrome c-dependent activation of procaspase-9. <i>FASEB Journal</i> , 1999 , 13, 2061-70	0.9	413
62	A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia. <i>Blood</i> , 1999 , 94, 1192-1200	2.2	606
61	Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. <i>Journal of Biological Chemistry</i> , 1999 , 274, 7987-92	5.4	246
60	Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells. <i>Cell Death and Differentiation</i> , 1999 , 6, 351-61	12.7	46
59	A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Groupe Ouest-Est du Centre des Leucémies aiguës myéloblastes. <i>Leukemia</i> , 1999 , 13, 524-9	10.7	45
58	p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. <i>Oncogene</i> , 1999 , 18, 1411-8	9.2	82

57	Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27Kip1 mediates its anti-apoptotic activity. <i>Oncogene</i> , 1999 , 18, 4839-47	9.2	78
56	FAS(CD95) ligand expression by tumor cell variants can be unrelated to their capacity to induce tolerance or immune rejection. <i>International Journal of Cancer</i> , 1999 , 82, 359-67	7.5	3
55	STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 256, 603-7	3.4	56
54	Proteases, proteolysis, and apoptosis. <i>Cell Biology and Toxicology</i> , 1998 , 14, 121-32	7.4	59
53	New insights into the kinetic resistance to anticancer agents. <i>Cytotechnology</i> , 1998 , 27, 225-35	2.2	11
52	Prolonged remission and autologous recovery in two patients with chronic myelogenous leukemia after graft failure of allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1998 , 21, 943-6	4.4	13
51	Cancer cell sensitization to fas-mediated apoptosis by sodium butyrate. <i>Cell Death and Differentiation</i> , 1998 , 5, 480-7	12.7	83
50	Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients. <i>Leukemia</i> , 1998 , 12, 34-43	10.7	38
49	Upregulation of CASP genes in human tumor cells undergoing etoposide-induced apoptosis. <i>Oncogene</i> , 1998 , 16, 2885-94	9.2	71
48	Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. <i>International Journal of Cancer</i> , 1998 , 77, 796-802	7.5	30
47	Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. <i>British Journal of Haematology</i> , 1998 , 102, 1015-24	4.5	65
46	PreB1 (CD10-) acute lymphoblastic leukemia: immunophenotypic and genomic characteristics, clinical features and outcome in 38 adults and 26 children. The Groupe d'Etude Immunologique des Leucémies. <i>Leukemia and Lymphoma</i> , 1998 , 28, 329-42	1.9	20
45	Glutathione is implied in the control of 7-ketocholesterol-induced apoptosis, which is associated with radical oxygen species production. <i>FASEB Journal</i> , 1998 , 12, 1651-63	0.9	178
44	BCR-ABL Delays Apoptosis Upstream of Procaspase-3 Activation. <i>Blood</i> , 1998 , 91, 2415-2422	2.2	87
43	BCR-ABL Delays Apoptosis Upstream of Procaspase-3 Activation. <i>Blood</i> , 1998 , 91, 2415-2422	2.2	4
42	New insights into the kinetic resistance to anticancer agents 1998 , 225-235		
41	Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. <i>Journal of Clinical Oncology</i> , 1997 , 15, 139-47	2.2	569
40	Heterogenous expression of CD15 in acute lymphoblastic leukemia: a study of ten anti-CD15 monoclonal antibodies in 158 patients. <i>Leukemia and Lymphoma</i> , 1997 , 25, 135-43	1.9	7

39	Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 783-9	9.7	258
38	Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure. <i>Bone Marrow Transplantation</i> , 1997 , 20, 63-5	4.4	13
37	The role of apoptosis in the pathogenesis and treatment of diseases. <i>European Respiratory Journal</i> , 1996 , 9, 1293-305	13.6	50
36	Diagnostic value of serum IL-6 level in monoclonal gammopathies. <i>British Journal of Haematology</i> , 1995 , 89, 243-9	4.5	24
35	Der(16)t(1;16)(q11;q11) in myelodysplastic syndromes: a new non-random abnormality characterized by cytogenetic and fluorescence in situ hybridization studies. <i>British Journal of Haematology</i> , 1995 , 90, 119-24	4.5	21
34	SERUM IL-6 CONCENTRATIONS IN LYMPHOMAS. <i>British Journal of Haematology</i> , 1995 , 90, 732-732	4.5	
33	Diagnostic value of serum IL-6 level in monoclonal gammopathies. <i>British Journal of Haematology</i> , 1995 , 89, 243-249	4.5	2
32	Cellular pharmacology of azatoxins (topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines. <i>International Journal of Cancer</i> , 1995 , 63, 268-75	7.5	14
31	Detection of apoptosis-associated DNA fragmentation using a rapid and quantitative filter elution assay. <i>Drug Development Research</i> , 1995 , 34, 138-144	5.1	24
30	A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 1994 , 33, 603-13	5.1	61
29	Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. <i>Leukemia and Lymphoma</i> , 1994 , 15, 21-32	1.9	75
28	Prognostic relevance of surface markers in adult de novo acute myeloblastic leukemias: a prospective study of the Groupe d'Etude Immunologique des Leucémies (G.E.I.L.). <i>Leukemia and Lymphoma</i> , 1994 , 13 Suppl 1, 7-10	1.9	3
27	Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. <i>International Journal of Cancer</i> , 1994 , 58, 85-94	7.5	15
26	Induction of a common pathway of apoptosis by staurosporine. <i>Experimental Cell Research</i> , 1994 , 211, 314-21	4.2	415
25	Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. <i>Cancer Investigation</i> , 1994 , 12, 530-42	2.1	190
24	Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors. <i>Experimental Cell Research</i> , 1993 , 207, 388-97	4.2	109
23	Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. <i>Journal of Antimicrobial Chemotherapy</i> , 1993 , 31, 161-9	5.1	73
22	Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent. <i>Biochemical Pharmacology</i> , 1993 , 45, 2449-56	6	46

21	Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia. <i>European Journal of Haematology</i> , 1992 , 48, 254-8	3.8	24
20	Prophylactic fluconazole and <i>Candida krusei</i> infections. <i>New England Journal of Medicine</i> , 1992 , 326, 891; author reply 892-3	59.2	45
19	Bone marrow necrosis and human parvovirus associated infection preceding an Ph1+ acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 1992 , 8, 415-9	1.9	16
18	New case of t(3;17)(q26;q22) as an additional change in a Philadelphia-positive chronic myelogenous leukemia in acceleration. <i>Cancer Genetics and Cytogenetics</i> , 1992 , 60, 90-2		10
17	High concentrations of intrathecal interleukin-6 in human bacterial and nonbacterial meningitis. <i>Journal of Infectious Diseases</i> , 1992 , 166, 428-31	7	61
16	Radiolabeling of DNA can induce its fragmentation in HL-60 human promyelocytic leukemic cells. <i>Experimental Cell Research</i> , 1992 , 203, 495-8	4.2	20
15	Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. <i>Journal of Clinical Oncology</i> , 1992 , 10, 1730-6	2.2	95
14	Itraconazole as Salvage Therapy in Invasive Pulmonary Aspergillosis Occurring during Amphotericin B Therapy in Neutropenic Patients. <i>Chemotherapy</i> , 1992 , 38, 50-51	3.2	3
13	Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1992 , 11, 722-5	5.3	35
12	Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. <i>American Journal of Hematology</i> , 1992 , 39, 163-71	7.1	52
11	Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. <i>Cancer</i> , 1991 , 68, 1714-9	6.4	37
10	Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice. <i>British Journal of Cancer</i> , 1990 , 62, 395-7	8.7	24
9	Association of a chromosomal 9,12 translocation with B cell precursor lymphoblastic blast crisis of a Ph+ chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 1989 , 72, 106-8	4.5	3
8	Immune mechanisms in HIV-related neuropathies. <i>Lancet, The</i> , 1989 , 2, 812-3	4.0	
7	Septicémie à <i>Trichosporon beigelii</i> (cutaneum) au cours d'une aplasie médullaire : échec du traitement prophylactique et curatif. <i>Médecine Et Maladies Infectieuses</i> , 1989 , 20, 160-162	4	
6	Disseminated aspergillosis revealed by thyroiditis in a renal allograft recipient. <i>Transplantation</i> , 1987 , 44, 839-40	1.8	12
5	Survenue d'une arthrite à <i>Candida tropicalis</i> chez un immuno-déprimé malgré une prophylaxie par le ketoconazole. <i>Médecine Et Maladies Infectieuses</i> , 1987 , 17, 93-95	4	
4	Systemic lupus erythematosus occurring in a patient with multiple myeloma. <i>Arthritis and Rheumatism</i> , 1986 , 29, 933-4		11

3 Strategies to Overcome Drug Resistance in Acute and Chronic Leukemias 315-347

2 RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis 2

1 The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia*, 10.7 76